Summary

Cross-species DNA methylation study design requires species-specific method selection: human, mouse, and chicken genomes differ substantially in CpG density, global methylation levels, and reference genome annotation quality, making a single protocol unsuitable across all three. This guide provides a practical decision framework — including a method-by-species summary table and decision tree — to help researchers select between WGBS, RRBS, MeDIP-seq, and methylation arrays based on species, research goal, sample availability, and budget.

Key Takeaways

• The chicken genome is globally hypomethylated relative to mammals and lacks DNMT3L, a cofactor required for high-level sperm methylation in mammals; this produces a distinct CpG methylation landscape that affects method choice and downstream interpretation
• Mouse has the lowest CpG dinucleotide observed/expected ratio (0.9%) among vertebrates (Kessler et al., BMC Biology, 2022), meaning RRBS covers approximately 2 million CpGs in mouse versus ~4 million in human under the same MspI + size-selection conditions
• RRBS is validated across human, mouse, and chicken and offers the best cost-to-coverage trade-off for CpG island-focused studies in all three species
• WGBS remains the gold standard for unbiased genome-wide coverage and is the only sequencing method that reliably captures non-CpG methylation, imprinting, and low-methylation regions in all three species
• The Illumina EPIC array is designed for human samples; only 1.6% of its probes (approximately 13,665 out of 866,836) align reliably to the mouse genome (Loyfer et al., PLoS One, 2018), and its utility for chicken is negligible without custom cross-species alignment
• For chicken and other non-model organisms, reference-free RRBS approaches such as RefFreeDMA provide a viable path when genome annotation quality is incomplete or absent

Why Species Biology Changes Your Method Choice

The choice of DNA methylation method is not purely a technical decision. It is, first, a biological one. Human, mouse, and chicken genomes differ in three properties that directly affect which assay will return interpretable data: CpG density, global methylation level, and methyltransferase repertoire. Getting this wrong means committing sequencing budget to a method that either misses the biologically relevant sites or produces a dataset that cannot be meaningfully interpreted against the species' known regulatory landscape.

For an overview of the available sequencing approaches and their underlying principles, see our overview of DNA methylation sequencing methods.

Human vs Mouse: CpG Density and What It Means for Coverage

In human, the CpG observed/expected ratio varies across the genome but averages approximately 1.1% — above the theoretical expectation given the overall GC content, reflecting the well-known enrichment of CpG sites at gene regulatory regions. In mouse, the same ratio is 0.9%, the lowest among the seven vertebrate species compared by Kessler et al. (BMC Biology, 2022). This is not a minor technical footnote. It means that the same MspI restriction digestion and 40–220 bp size selection used in standard RRBS yields approximately 4 million CpGs in human samples, but only approximately 2 million in mouse — because there are fewer CCGG target sites in the mouse genome to begin with.

For WGBS, the implication is different: the mouse genome contains approximately 21 million CpGs versus 28 million in human. Deep sequencing requirements scale with genome size and CpG count. This is manageable, but researchers planning multi-sample mouse cohorts should plan sequencing depth accordingly, not simply copy protocols from human studies.

Chicken: A Distinct Methylation Landscape

The chicken methylome is structurally divergent from both human and mouse in ways that go beyond CpG density. A comparative WGBS analysis of primary fibroblasts from seven vertebrate species (Kessler et al., BMC Biology, 2022) demonstrated that the chicken genome is hypomethylated relative to all mammalian species in the comparison — a finding that has important consequences for method sensitivity, DMR calling thresholds, and the interpretation of low-methylation regions.

The mechanistic basis for this hypomethylation traces back to a single gene loss. DNMT3L — which in mammals acts as a catalytically inactive cofactor that stimulates de novo methylation by DNMT3A and DNMT3B — is absent from all bird and monotreme genomes, having been gained by gene duplication in the common amniote ancestor and subsequently lost in the avian lineage (Lister et al., Communications Biology, 2021). Without DNMT3L, chicken sperm DNA is globally hypomethylated compared to mammalian sperm — a difference not seen in somatic tissues to the same degree, but one that illustrates the mechanistic divergence of the chicken methylation machinery.

In practical terms, the lower baseline methylation means that DMR detection thresholds calibrated for mammalian tissues will call more false positives in chicken, and that low-methylated regions (LMRs) — which are biologically meaningful regulatory elements in mammals — are more abundant and less discriminating in chicken.

Figure 1. Human, mouse, and chicken present distinct DNA methylation landscapes. Mouse has the most CpG-depleted genome among vertebrates; chicken is globally hypomethylated due to DNMT3L absence. Method selection must account for these biological differences, not assume cross-species equivalence.

Method-by-Species Summary: Best Fit at a Glance

The table below summarizes method suitability across the three species and the most common research goals. No single method is universally optimal; the right choice depends on the combination of species, biological question, sample quantity, and budget.

Planning a cross-species DNA methylation project? Our DNA methylation analysis services support WGBS, RRBS, and MeDIP-seq across a wide range of species and sample types. Request a method consultation →

Reading the Table: Three Decision Rules

Rule 1 — If your species is chicken and your budget allows it: WGBS is the most informative choice because it captures the full spectrum of methylation variation including non-CpG contexts and LMRs, which are relatively more abundant in chicken. RRBS is a practical and validated alternative when sample numbers are large or budgets are constrained.

Rule 2 — If your goal is a large human cohort (n > 20) and single-base resolution is not required at every CpG: The Illumina EPIC array offers the best throughput-to-cost ratio. RRBS is the sequencing-based alternative when array coverage is insufficient for the research question.

Rule 3 — If you are running the same experiment across all three species: RRBS is the only sequencing-based method validated in all three, producing comparable CpG island and promoter-region coverage despite the CpG density differences noted above. Do not use the EPIC array as the human arm of a cross-species study — it cannot serve as an equivalent to RRBS or WGBS in mouse or chicken.

WGBS vs RRBS: When Each Method Is the Right Choice

These two bisulfite-based methods represent the most common decision point for researchers across all three species. Both use sodium bisulfite conversion to distinguish methylated from unmethylated cytosines at single-base resolution. The difference is scope: WGBS covers every cytosine in the genome; RRBS selectively enriches CpG-dense regions through MspI restriction digestion and size selection.

For a technical introduction to RRBS, including the MspI cleavage mechanism and library preparation workflow, see how RRBS works. For WGBS workflow details and data analysis considerations, see our WGBS analysis workflow resource.

When WGBS Is the Right Investment

WGBS is not simply a more expensive version of RRBS. It accesses biological information that RRBS structurally cannot:

• Non-CpG methylation: In brain tissue, widespread non-CpG methylation (CHG and CHH contexts) has been documented in both human and mouse, and is emerging as a feature of chicken neural and germline tissue. RRBS, which enriches for CCGG-containing fragments, does not cover non-CpG sites systematically.
• Genomic imprinting: Imprinted regions in mouse are well characterized, but the full imprint control region landscape requires genome-wide coverage. RRBS captures many imprinted loci, but not all — particularly those in CpG-poor flanking regions.
• Low-methylation regions in chicken: The abundance of LMRs in the chicken methylome makes whole-genome coverage particularly valuable for regulatory interpretation. Limiting analysis to CpG island-proximal regions via RRBS may miss a substantial fraction of the biologically active methylation variation in chicken.
• Allele-specific methylation in mouse genetic crosses: Distinguishing parent-of-origin methylation requires high-depth, phased-read analysis that RRBS depth is insufficient to support reliably.

The practical trade-off is cost and DNA input. WGBS requires higher-quality gDNA and deeper sequencing than RRBS. For samples where these are not constraints, WGBS is the first-choice method across all three species.

Figure 2. WGBS provides complete genome-wide coverage including non-CpG contexts; RRBS offers cost-effective CpG island enrichment validated across all three species. The right choice depends on biological question, sample size, and budget.

When RRBS Is Sufficient (and More Practical)

RRBS was validated simultaneously across nine vertebrate species — including human, mouse, rat, chicken, and zebrafish — using a reference-free approach (Schultz et al., Genome Biology, 2015), establishing it as the most broadly validated bisulfite sequencing method for cross-species work. For the majority of research questions in all three species, RRBS provides sufficient coverage:

• CpG island and promoter methylation: Both human (~4M CpGs) and mouse (~2M CpGs) RRBS datasets capture the substantial majority of CpG island-associated promoter methylation, which is where most transcriptional regulation is anchored.
• Multi-sample cohort studies: RRBS's lower cost per sample makes biological replication feasible. Running n=6 replicates per group for RRBS is standard; for WGBS, the same n requires substantially higher budget allocation.
• Chicken studies with known reference genome: When GalGal6 annotation is used and the research question focuses on gene regulatory regions, RRBS provides a workable methylome at a fraction of WGBS cost.

For low-input samples — single cells, scarce clinical biopsies, or early-stage embryos — standard RRBS and WGBS protocols have been extended by methods such as PBAT-WGBS. For an overview of low-input WGBS approaches applicable to scarce samples, see our PBAT-WGBS resource.

Species-Specific Design Considerations

Human Studies: When Arrays Are Appropriate and When They Are Not

The Illumina EPIC array profiles more than 850,000 CpG sites and is optimized for human somatic tissue methylation. For large cohort studies (n > 20–50), epidemiological designs, and epigenetic clock applications, the array offers throughput and cost advantages that sequencing-based methods cannot match at equivalent n.

The critical constraint is that the EPIC array is designed for human samples only. When Loyfer et al. (PLoS One, 2018) systematically aligned EPIC probe sequences to the mouse genome, only 13,665 probes (1.6% of 866,836 total) achieved high-quality alignment to conserved CpGs. Of these, the mouse-applicable probes showed good concordance with MBD-seq at individual loci, but detected no significant age-associated differential methylation in mouse liver — a clear signal that the EPIC's coverage of biologically relevant mouse methylation is structurally limited.

For chicken, the situation is more extreme: the array's probes target human-specific sequences, and cross-species alignment to the chicken genome is negligible.

The practical implication: if you are using the EPIC array for a human cohort and want to replicate findings in a mouse model, you cannot use the same platform. RRBS or WGBS is required for the mouse arm of the study. This is not a minor methodological footnote — it affects study design, QC strategy, and the statistical framework for cross-species validation.

A mammalian-conserved array (Lu et al., Nature Communications, 2022) covering ~36,000 conserved CpGs across more than 200 mammalian species was developed specifically to address the cross-mammalian comparison gap. This array does not include birds, making it unsuitable for chicken studies, but it provides a viable option for human-mouse comparative epigenetic aging or evolution studies at lower coverage than WGBS.

Mouse Studies: CpG Depletion, Fragment Selection, and Imprinting

Mouse is the most CpG-depleted vertebrate genome studied so far. The practical consequence for RRBS is that MspI digestion produces fewer fragments in the 40–220 bp size selection window — approximately 2 million usable CpGs versus 4 million in human. This is not a failure of the method; it reflects the biology. For mouse promoter and CpG island methylation studies, 2 million CpGs provides adequate coverage of known regulatory elements.

Where mouse methylation studies require WGBS rather than RRBS is in two specific research contexts. First, genomic imprinting analysis: mouse is the primary model organism for imprinting biology, and the full set of imprint control regions and differentially methylated domains requires genome-wide coverage. Second, allele-specific methylation in mouse genetic crosses: parent-of-origin methylation differences require high-depth, phased-read analysis that RRBS depth is insufficient to support reliably.

Mouse-specific DNA methylation microarrays do not currently exist in the commercial sense that human arrays do. Bisulfite sequencing remains the primary quantitative tool for mouse methylation studies, with RRBS as the cost-effective first-pass method and WGBS as the definitive approach.

Chicken Studies: Working With a Hypomethylated Genome and Incomplete Annotations

Chicken methylation studies face two challenges that are absent or less severe in human and mouse work: the globally hypomethylated background and variable reference genome annotation quality.

On the biological side, the hypomethylated background — documented by Kessler et al. 2022 and mechanistically linked to DNMT3L loss by Lister et al. 2021 — means that standard DMR calling thresholds developed for mammalian tissues will overcall in chicken. A methylation difference that is biologically meaningful in human or mouse (say, a 20% change at a promoter CpG island) may represent a different regulatory significance in the context of the chicken's lower baseline. Researchers should calibrate their DMR thresholds using chicken-specific reference datasets rather than directly applying mammalian benchmarks.

On the technical side, the current chicken reference genome (GalGal6) provides good coverage of protein-coding gene annotation, but regulatory element annotation — enhancers, lncRNA promoters, CTCF binding sites — is substantially less complete than in human or mouse. For studies focused on promoter-proximal methylation, GalGal6 + Ensembl annotation is workable. For broader regulatory interpretation, researchers should supplement with chicken ENCODE data where available or adopt a reference-free RRBS approach.

Reference-free RRBS (implemented in tools such as RefFreeDMA, validated across nine species by Schultz et al. 2015) identifies differentially methylated regions without relying on a complete, high-quality genome assembly. Reads are assembled de novo, and differential methylation is called between sample groups directly. This approach sacrifices positional precision but is robust to annotation gaps and is particularly useful in chicken genetic studies where the specific breed or line of interest lacks a high-quality assembled genome.

For tissue-specific chicken methylation questions where a reference exists and annotation is sufficient, standard RRBS against GalGal6 is the preferred starting point.

Working with chicken samples or another non-standard species? Our team can advise on protocol adaptation and reference genome strategy. Contact us to discuss your project →

Figure 3. Method selection decision tree by species and research goal. Start with species, then research objective, then practical constraints to identify the appropriate methylation assay.

Study Design Decisions That Cut Across All Three Species

Method selection is the first design decision, but not the only one. Three study design questions apply regardless of which species is being studied, and getting them wrong can undermine the most carefully chosen method.

For a broader framework covering study design, replicate strategy, and analysis planning across DNA methylation project types, see our DNA methylation study design strategy resource.

Replication, Sample Size, and Statistical Power for DMR Detection

The statistical power to detect differentially methylated regions depends on three variables: the magnitude of the methylation difference, the variance across biological replicates, and the number of replicates. For all three species, published guidelines suggest a minimum of three biological replicates per group for basic DMR calling, with six or more preferred for studies with modest effect sizes or heterogeneous samples.

In human studies, inter-individual genetic variation is the dominant source of methylation variance across samples. In mouse studies using inbred strains, genetic background variance is controlled — but mouse models have other sources of epigenomic variance including litter effects, cage effects, and age-dependent drift. In chicken, breed-specific methylation differences can be substantial; cohorts should be drawn from the same breed and age class to avoid confounding.

DNA input requirements differ by method and must be planned at the sample collection stage. WGBS typically requires higher-quality gDNA input than RRBS; array-based methods accept bisulfite-converted DNA at very low input. For FFPE or archival samples — common in human biobanking but rare in mouse and chicken — RRBS and array methods are more robust to degraded input than WGBS.

Pairing DNA Methylation With RNA-Seq Across Species

Integrating DNA methylation data with gene expression data is standard practice for all three species. The pairing logic is the same: genes with differentially methylated promoters and concordant differential expression are high-confidence regulatory candidates. But the implementation differs by method.

For WGBS and RRBS, pairing with matched RNA-seq from the same tissue aliquot maximizes interpretive power. Gene-level integration is straightforward using standard annotation-based overlap between DMRs and promoter windows. For the EPIC array in human studies, the integration is equally standard; thousands of published pipelines exist for EPIC + RNA-seq correlation analysis in cancer and developmental biology.

For chicken, integrating DNA methylation with RNA-seq is particularly valuable because the chicken regulatory annotation is incomplete: expression data from the same sample provides functional context for methylation changes at unannotated regulatory regions. This integration is a core deliverable of our integrated RNA-seq and epigenomic data analysis service, which supports cross-species analysis pipelines.

Ready to plan your cross-species methylation project? Our team can review your species, tissue types, sample numbers, and research goals to recommend the right method combination. Contact us to discuss your study design →

Frequently Asked Questions